SCHEMBL385553

SCHEMBL385553

COCCOc1ccc(-c2cc(-c3ccc(O)c(C)c3)nc(=O)[nH]2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 8/20 0.66
PIM1 P11309 3/20 0.66
GSK3B P49841 2/20 0.66
CSNK2A1 P68400 2/20 0.66
CSNK2A2 P19784 1/20 0.66
CLK1 P49759 1/20 0.66
CSNK2B P67870 1/20 0.66
CSNK2A3 Q8NEV1 1/20 0.66
CXCL12 P48061 1/20 0.53
KDM4E B2RXH2 2/20 0.50
GPR84 Q9NQS5 1/20 0.43
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
EGFR P00533 3/20 0.39
CSF1R P07333 3/20 0.39
XDH P47989 2/20 0.38
MAPK13 O15264 1/20 0.38
DAPK3 O43293 1/20 0.38
ROCK2 O75116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383300 0.90 CDC7 (0.64) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL385467 0.88 PIM1 (0.54) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL385827 0.88 PIM1 (0.57) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL385178 0.86 CDC7 (0.75) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL3332263 0.85 CDC7 (0.56) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL3327542 0.85 CDC7 (0.69) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL3325796 0.84 PIM1 (0.54) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL385748 0.83 PIM1 (0.67) CDC7PIM1GSK3BCSNK2A1CSNK2A2
Hydrochloric Acid SCHEMBL386384 0.83 PIM1 (0.66) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL3328617 0.81 PIM1 (0.51) CDC7PIM1GSK3BCSNK2A1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US claimed
EP-1948617-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2011-07-27 EP claimed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US claimed
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US disclosed
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US disclosed
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US disclosed
EP-1948617-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2011-07-27 EP disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators CSNK2A1, CSNK1A1, CSNK2A2 CDC7 536/4885PIM1 429/4885GSK3B 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.